These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 10936517)
1. C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles. Furlong ST; Dutta AS; Coath MM; Gormley JJ; Hubbs SJ; Lloyd D; Mauger RC; Strimpler AM; Sylvester MA; Scott CW; Edwards PD Immunopharmacology; 2000 Jul; 48(2):199-212. PubMed ID: 10936517 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. Sahu A; Kay BK; Lambris JD J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942 [TBL] [Abstract][Full Text] [Related]
3. A new generation of potent complement inhibitors of the Compstatin family. López de Victoria A; Gorham RD; Bellows-Peterson ML; Ling J; Lo DD; Floudas CA; Morikis D Chem Biol Drug Des; 2011 Jun; 77(6):431-40. PubMed ID: 21352502 [TBL] [Abstract][Full Text] [Related]
4. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Nilsson B; Larsson R; Hong J; Elgue G; Ekdahl KN; Sahu A; Lambris JD Blood; 1998 Sep; 92(5):1661-7. PubMed ID: 9716594 [TBL] [Abstract][Full Text] [Related]
5. Studies of structure-activity relations of complement inhibitor compstatin. Soulika AM; Morikis D; Sarrias MR; Roy M; Spruce LA; Sahu A; Lambris JD J Immunol; 2003 Aug; 171(4):1881-90. PubMed ID: 12902490 [TBL] [Abstract][Full Text] [Related]
6. Evolution of compstatin family as therapeutic complement inhibitors. Huang Y Expert Opin Drug Discov; 2018 May; 13(5):435-444. PubMed ID: 29402126 [TBL] [Abstract][Full Text] [Related]
7. Compstatin: a complement inhibitor on its way to clinical application. Ricklin D; Lambris JD Adv Exp Med Biol; 2008; 632():273-92. PubMed ID: 19025129 [TBL] [Abstract][Full Text] [Related]
8. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Fiane AE; Mollnes TE; Videm V; Hovig T; Høgåsen K; Mellbye OJ; Spruce L; Moore WT; Sahu A; Lambris JD Xenotransplantation; 1999 Feb; 6(1):52-65. PubMed ID: 10355733 [TBL] [Abstract][Full Text] [Related]
9. Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3. Soulika AM; Holland MC; Sfyroera G; Sahu A; Lambris JD Mol Immunol; 2006 May; 43(12):2023-9. PubMed ID: 16472861 [TBL] [Abstract][Full Text] [Related]
10. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Mastellos DC; Yancopoulou D; Kokkinos P; Huber-Lang M; Hajishengallis G; Biglarnia AR; Lupu F; Nilsson B; Risitano AM; Ricklin D; Lambris JD Eur J Clin Invest; 2015 Apr; 45(4):423-40. PubMed ID: 25678219 [TBL] [Abstract][Full Text] [Related]
11. Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin. Sahu A; Soulika AM; Morikis D; Spruce L; Moore WT; Lambris JD J Immunol; 2000 Sep; 165(5):2491-9. PubMed ID: 10946275 [TBL] [Abstract][Full Text] [Related]
12. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. Janssen BJ; Halff EF; Lambris JD; Gros P J Biol Chem; 2007 Oct; 282(40):29241-7. PubMed ID: 17684013 [TBL] [Abstract][Full Text] [Related]